Founded in Barcelona in 2006, Pangaea Oncology is a medical services company focused on precision oncology, personalized medicine based on genetic analyses to improve survival and quality of life for cancer patients.
The company has two main areas of activity: (i) its clinical care division, the Dr. Rosell Oncology Institute (IOR). Based on the concept of personalized medicine, IOR delivers medical oncology services and related activities at four of the largest hospitals of the Quirónsalud Group in Catalonia; (ii) its Diagnostic and R & D services division, providing diagnostic and in-vitro services to IOR patients and Pangaea's portfolio of pharmaceutical clients, including over 15 multinationals. Pangaea is highly invested in technology, focusing on the development of innovative, proprietary diagnostic techniques (its main commercialized asset is Liquid Biopsy), and development of targeted drugs - to early clinical trial stages - through a strategic agreement with Cancer Research Technology, UK.
The synergy between these areas forms the foundation of Pangaea's future growth strategy.